Special Issue

Novel Therapeutic Targets in Cancer

Message from the Guest Editor

I would like to inform you that the *Pharmaceuticals* Special Issue "Novel Therapeutic Targets in Cancer" is now accepting manuscripts for publication. In recent vears, significant advances have been made in the management of cancer with the introduction of targeted therapies and immunotherapy. However, there continues to be an unmet clinical need for those patients who progress while on novel therapies. Thus, the identification of new mechanisms involved in tumor progression is critical to improve survival in this population. The scope of this Special Issue is to publish translational articles with the potential to provide a rationale for new strategies in cancer treatment. Appropriate subjects include novel molecular targets. intrinsic pathways involved in tumor immune escape mechanisms, drug development, physiological and pharmacological bases of drug action, and metabolism. Contributions to this issue include submission of original articles, review, short communications, and editorials.

Guest Editor

Dr. Carlo Marchetti

Anschutz Medical Campus, University of Colorado Denver, Denver, CO, USA

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/45657

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

